PLEURAL MALIGNANT MESOTHELIOMA
Clinical trials for PLEURAL MALIGNANT MESOTHELIOMA explained in plain language.
Never miss a new study
Get alerted when new PLEURAL MALIGNANT MESOTHELIOMA trials appear
Sign up with your email to follow new studies for PLEURAL MALIGNANT MESOTHELIOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy after radiation shows promise in rare lung cancer
Disease control CompletedThis early-phase trial tested whether giving the immunotherapy drug pembrolizumab (Keytruda) after radiation therapy is safe for people with malignant pleural mesothelioma, a rare cancer of the lung lining. Twenty-five participants received radiation followed by pembrolizumab. Th…
Matched conditions: PLEURAL MALIGNANT MESOTHELIOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Immune booster shows promise against rare cancer
Disease control CompletedThis study tested a drug called pembrolizumab in 65 people with malignant mesothelioma, a rare cancer of the lining around the lungs or abdomen. The drug works by helping the immune system attack cancer cells. The goal was to see if it could shrink tumors or slow the disease, but…
Matched conditions: PLEURAL MALIGNANT MESOTHELIOMA
Phase: PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC